SAB BIOTHERAPEUTICS, INC. Operating Lease, Expense
SAB BIOTHERAPEUTICS, INC. (SABS) reported Operating Lease, Expense of $1.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-03-09
- SAB BIOTHERAPEUTICS, INC. operating lease, expense for fiscal 2025 was $1.10M, a 37.50% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. operating lease, expense for fiscal 2024 was $800.00K, a 20.00% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. operating lease, expense for fiscal 2023 was $1.00M.
| Period end | Operating Lease, Expense 12 month |
|---|---|
| 2025-12-31 | $1.10M 10-K · filed 2026-03-09 |
| 2024-12-31 | $800.00K 10-K · filed 2026-03-09 |
| 2023-12-31 | $1.00M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |